BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Muna Therapeutics Doses First Subjects in Phase 1 Trial of TREM2 Agonist MNA-001 for Alzheimer’s Disease

MNA-001 has best-in-class potential based on preclinical data demonstrating ability to significantly reduce neurotoxic amyloid burden and reprogram microgl...

November 11, 2025 | News

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

Takeda’s Mezagitamab Shows Sustained Kidney Function and Proteinuria Reduction Through 18-Month Follow-Up in IgA Nephropathy

Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 ...

November 10, 2025 | News

PolyActiva and RareSight Forge Strategic Partnership to Develop Sustained-Release Therapies for Rare Pediatric Retinal Diseases

Partnership Leverages PolyActiva’s PREZIA™ Drug Delivery Platform Technology and RareSight’s Expertise in Rare Diseases to Advance Nove...

November 07, 2025 | News

Tenpoint Therapeutics and Zhaoke Ophthalmology Advance BRIMOCHOL™ PF Toward Global Market with NDA Filing in South Korea

Submission of New Drug Application (NDA) in South Korea by Zhaoke Ophthalmology Ltd.’s local partner, Kwangdong Pharmaceutical Co., Ltd., marks the...

November 07, 2025 | News

NEXT Oncology Expands to Japan Through Partnership with Kansai Medical University

With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. NEXT Oncology, an Avac...

November 07, 2025 | News

Takeda’s QDENGA Trial Confirms Sustained Protection and Favourable Safety Over Seven Years

Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the ...

November 06, 2025 | News

iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial

ILKN421H is a novel lipid nanoparticle (LNP)-formulated mRNA encoding a non-alpha HSA–IL-2v fusion protein and dominantly expressed in lymphoid org...

November 05, 2025 | News

AVEO and HiberCell Partner to Develop First-in-Human PERK Inhibitor for Kidney Cancer

First-in-Human PERK inhibitor (HC-5404) to be developed in combination with AVEO's FOTIVDA® (tivozanib) for RCC – – AVEO...

November 05, 2025 | News

Bio-Techne and Nucleai Demonstrate Predictive Power of Spatial Biomarkers in Melanoma

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomar...

November 05, 2025 | News

Akeso Secures Fourth Breakthrough Therapy Designation for Ivonescimab in Combination Therapy for Triple-Negative Breast Cancer

Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for fi...

November 04, 2025 | News

Endeavor BioMedicines’ Taladegib Becomes First Investigational IPF Therapy to Receive EMA PRIME Designation

Taladegib is the first and only investigational IPF therapy to receive PRIME designation Phase 2b WHISTLE-PF trial is on track to complete enrollment ...

November 04, 2025 | News

NovaBridge Subsidiary Visara Assigns Exclusive License for VIS-101 to Everest Medicines to Advance Treatment for Wet AMD Across Asia

NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet...

November 03, 2025 | News

Alpha Fusion Initiates Phase I Trial of Alpha-Emitting Radiopharmaceutical af-001 for Differentiated Thyroid Cancer

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – ...

November 03, 2025 | News

Stay Connected